The U.S. Senate Finance Committee’s latest drug pricing legislation includes 340B language not seen before in earlier House and Senate versions.

Senate Finance Committee’s New Drug Pricing Text Includes a New 340B Provision

The U.S. Senate Finance Committee’s latest drug pricing legislation includes language, not seen before in earlier House and Senate versions, about denying 340B covered entities’ access to government-negotiated lower prices on drugs covered under Medicare.

The committee released the 1,180-page text of its changes to the House-passed Build Back Better Act on Saturday. Groups and law firms that represent 340B entities said yesterday they were still studying the Finance Committee text and seeking more information before reaching conclusions about its implications for 340B program participants.

The U.S. Senate Finance Committee’s latest drug pricing legislation includes language, not seen before in earlier House and Senate versions, about denying 340B covered entities’ access to government-negotiated lower prices on drugs covered under Medicare.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer